{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:26Z","timestamp":1794047366920,"version":"4.8.0"},"reference-count":37,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory or intolerant to prior therapies. Significant molecular responses were achieved within 3-6 months in 81% of patients with phenotypic driver mutations in JAK2, CALR and MPL. Here, we investigated the dynamics of additional somatic mutations in response to imetelstat. At study entry, 50% of patients carried 1-5 additional mutations in the genes ASXL1, CBL, DNMT3A, EZH2, IDH1, SF3B1, TET2, TP53 and U2AF1. Three patients with baseline mutations also had late-emerging mutations in TP53, IDH1 and TET2. Most clones with additional mutations were responsive to imetelstat and decreased with the driver mutation, including the poor prognostic ASXL1, EZH2 and U2AF1 mutations while SF3B1 and TP53 mutations were associated with poorer molecular response. Overall, phenotypic driver mutation response was significantly deeper in patients without additional mutations (P = 0.04) and correlated with longer duration of response. In conclusion, this detailed molecular analysis of highly pretreated and partly resistant patients with essential thrombocythemia reveals a high individual patient complexity. Moreover, imetelstat demonstrates potential to inhibit efficiently co-incident mutations occurring in neoplastic clones in patients with essential thrombocythemia. (ClinicalTrials.gov number, NCT01243073. N Engl J Med 2015; 373:920-928, DOI: 10.1056\/NEJMoa1503479.)<\/jats:p>","DOI":"10.3324\/haematol.2020.252817","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T14:50:46Z","timestamp":1596120646000},"page":"2397-2404","source":"Crossref","is-referenced-by-count":9,"title":["Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat"],"prefix":"10.3324","volume":"106","author":[{"family":"Elisabeth Oppliger Leibundgut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Monika Haubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Bart Burington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Oliver G. Ottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gary Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Olatoyosi Odenike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Michael A. McDevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alexander R\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"David S. Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gabriela M. Baerlocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"28926","doi-asserted-by":"crossref","unstructured":"Ouellette MM, Wright WE, Shay JW. Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011; 15(7):1433-1442.","DOI":"10.1111\/j.1582-4934.2011.01279.x"},{"key":"28927","doi-asserted-by":"crossref","unstructured":"Florena AM, Tripodo C, Di Bernardo A. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis. J Clin Pathol. 2009; 62(4):331-338.","DOI":"10.1136\/jcp.2007.054353"},{"key":"28928","doi-asserted-by":"crossref","unstructured":"Baerlocher GM, Haubitz M, Braschler TR. Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia. Blood Adv. 2019; 3(22):3724-3728.","DOI":"10.1182\/bloodadvances.2019000167"},{"key":"28929","doi-asserted-by":"crossref","unstructured":"Baerlocher GM, Oppliger Leibundgut E. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015; 373(10):920-928.","DOI":"10.1056\/NEJMoa1503479"},{"key":"28930","doi-asserted-by":"crossref","unstructured":"Milosevic Feenstra JD, Nivarthi H, Gisslinger H. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016; 127(3):325-332.","DOI":"10.1182\/blood-2015-07-661835"},{"key":"28931","doi-asserted-by":"crossref","unstructured":"Cabagnols X, Favale F, Pasquier F. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016; 127(3):333-342.","DOI":"10.1182\/blood-2015-07-661983"},{"key":"28932","doi-asserted-by":"crossref","unstructured":"Nangalia J, Massie CE, Baxter EJ. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.","DOI":"10.1056\/NEJMoa1312542"},{"key":"28933","doi-asserted-by":"crossref","unstructured":"Lundberg P, Karow A, Nienhold R. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014; 123(14):2220-2228.","DOI":"10.1182\/blood-2013-11-537167"},{"key":"28934","doi-asserted-by":"crossref","unstructured":"Vainchenker W, Kralovics R.. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017; 129(6):667-679.","DOI":"10.1182\/blood-2016-10-695940"},{"key":"28935","doi-asserted-by":"crossref","unstructured":"Harutyunyan A, Klampfl T, Cazzola M, Kralovics R.. p53 lesions in leukemic transformation. N Engl J Med. 2011; 364(5):488-490.","DOI":"10.1056\/NEJMc1012718"},{"key":"28936","doi-asserted-by":"crossref","unstructured":"Cerquozzi S, Tefferi A.. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015; 5(11):e366.","DOI":"10.1038\/bcj.2015.95"},{"key":"28937","doi-asserted-by":"crossref","unstructured":"Tefferi A, Lasho TL, Guglielmelli P. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016; 1(1):21-30.","DOI":"10.1182\/bloodadvances.2016000216"},{"key":"28938","doi-asserted-by":"crossref","unstructured":"Grinfeld J, Nangalia J, Baxter EJ. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018; 379(15):1416-1430.","DOI":"10.1056\/NEJMoa1716614"},{"key":"28939","doi-asserted-by":"crossref","unstructured":"Tefferi A, Guglielmelli P, Lasho TL. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020; 189(2):291-302.","DOI":"10.1111\/bjh.16380"},{"key":"28940","doi-asserted-by":"crossref","unstructured":"Verger E, Cassinat B, Chauveau A. Clinical and molecular response to interferon- alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015; 126(24):2585-2591.","DOI":"10.1182\/blood-2015-07-659060"},{"key":"28941","doi-asserted-by":"crossref","unstructured":"Kiladjian JJ, Masse A, Cassinat B. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010; 24(8):1519-1523.","DOI":"10.1038\/leu.2010.120"},{"key":"28942","doi-asserted-by":"crossref","unstructured":"Patel KP, Newberry KJ, Luthra R. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015; 126(6):790-797.","DOI":"10.1182\/blood-2015-03-633404"},{"key":"28943","doi-asserted-by":"crossref","unstructured":"Tefferi A, Lasho TL, Begna KH. A Pilot Study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015; 373(10):908-919.","DOI":"10.1056\/NEJMoa1310523"},{"key":"28944","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"28945","doi-asserted-by":"crossref","unstructured":"Barosi G, Birgegard G, Finazzi G. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009; 113(20):4829-4833.","DOI":"10.1182\/blood-2008-09-176818"},{"key":"28946","doi-asserted-by":"crossref","unstructured":"Adzhubei IA, Schmidt S, Peshkin L. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7(4):248-249.","DOI":"10.1038\/nmeth0410-248"},{"key":"28947","doi-asserted-by":"crossref","unstructured":"Pratcorona M, Abbas S, Sanders MA. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012; 97(3):388-392.","DOI":"10.3324\/haematol.2011.051532"},{"key":"28948","doi-asserted-by":"crossref","unstructured":"Gelsi-Boyer V, Trouplin V, Adelaide J. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145(6):788-800.","DOI":"10.1111\/j.1365-2141.2009.07697.x"},{"key":"28949","doi-asserted-by":"crossref","unstructured":"Langemeijer SM, Kuiper RP, Berends M. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009; 41(7):838-842.","DOI":"10.1038\/ng.391"},{"key":"28950","doi-asserted-by":"crossref","unstructured":"Rychlik W. OLIGO 7 primer analysis software. Methods Mol Biol. 2007; 402:35-60.","DOI":"10.1007\/978-1-59745-528-2_2"},{"key":"28951","doi-asserted-by":"crossref","unstructured":"Untergasser A, Cutcutache I, Koressaar T. Primer3--new capabilities and interfaces. Nucleic Acids Res. 2012; 40(15):e115.","DOI":"10.1093\/nar\/gks596"},{"key":"28952","doi-asserted-by":"crossref","unstructured":"Jones AV, Cross NC. Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol. 2013; 4(4):237-253.","DOI":"10.1177\/2040620713489144"},{"key":"28953","doi-asserted-by":"crossref","unstructured":"Nangalia J, Nice FL, Wedge DC. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. 2015; 100(11):e438-442.","DOI":"10.3324\/haematol.2015.129510"},{"key":"28954","doi-asserted-by":"crossref","unstructured":"Ortmann CA, Kent DG, Nangalia J. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015; 372(7):601-612.","DOI":"10.1056\/NEJMoa1412098"},{"key":"28955","doi-asserted-by":"crossref","unstructured":"Debarri H, Lebon D, Roumier C. IDH1\/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2015; 6(39):42345-42353.","DOI":"10.18632\/oncotarget.5645"},{"key":"28956","doi-asserted-by":"crossref","unstructured":"Jeziskova I, Musilova M, Culen M. Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML. Int J Hematol. 2015; 102(5):553-557.","DOI":"10.1007\/s12185-015-1856-3"},{"key":"28957","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Fontanillas P, Flannick J. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-2498.","DOI":"10.1056\/NEJMoa1408617"},{"key":"28958","doi-asserted-by":"crossref","unstructured":"Zink F, Stacey SN, Norddahl GL. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017; 130(6):742-752.","DOI":"10.1182\/blood-2017-02-769869"},{"key":"28959","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019; 366(6465):eaan4673.","DOI":"10.1126\/science.aan4673"},{"key":"28960","doi-asserted-by":"crossref","unstructured":"Boiocchi L, Hasserjian RP, Pozdnyakova O. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol. 2019; 86:1-11.","DOI":"10.1016\/j.humpath.2018.11.022"},{"key":"28961","doi-asserted-by":"crossref","unstructured":"Kubesova B, Pavlova S, Malcikova J. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018; 32(2):450-461.","DOI":"10.1038\/leu.2017.230"},{"key":"28962","doi-asserted-by":"crossref","unstructured":"Montalban-Bravo G, Takahashi K, Patel K. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic\/ myeloproliferative neoplasms. Oncotarget. 2018; 9(11):9714-9727.","DOI":"10.18632\/oncotarget.23882"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9840\/71141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9840\/71142","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9840\/71141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:53Z","timestamp":1794045473000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.252817","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,30]]}}}